Conversion of Stable Kidney Transplant Recipients From a Twice-Daily to Once-Daily Everolimus Regimen

Transplantation Proceedings

Volumn 42, Issue 4, 2010, Pages 1312-1313

  Carmellini, M ^a   Collini, A ^a   Ruggieri, G ^a   Bernini, M ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; MORNING DOSAGE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGED; CADAVER; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SIROLIMUS; TISSUE DONORS;

EID: 77952559922     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.03.098     Document Type: Article

References (9)

1. Pinsky B.W., Takemoto S.K., Lentine K.L., et al. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant 9 (2009) 2597
2. Wente M.N., Sauer P., Mehrabi A., et al. Review of the clinical experience with a modified release form of tacrolimus [FK506E(MR4)] in transplantation. Clin Transplant 20 Suppl 17 (2006) 80
3. Kahan B.D., Wong R.L., Carter C., et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation 68 (1999) 1100
4. Neumayer H.H., Paradis K., Korn A., et al. Entry-into-human study with the novel immunosiuppressant SDZ RAD in stable renal transplant recipients. J Clin Pharmacol 48 (1999) 694
5. Kirchner G.I., Winkler M., Mueller L., et al. Pharmacokinetics of SDZ RAD and cyclosporin including yheir metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol 50 (2000) 449
6. Kovarik J.M., Kahan B.D., Kaplan B., et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the forst post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 69 (2001) 48
7. Sanchez-Fructuoso A.I. Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 4 (2008) 807
8. Tarantino A., Passerini P., Campise M., et al. Is cyclosporine in renal-transplant recipients more effective when given twice a day than in a single daily dose?. Transplantation 78 (2004) 675
9. Alloway R., Steinberg S., Khalil K., et al. Conversion of stable kidney transplant recipients from a twice daily prograf-baswed regijmen to a once daily modified release tacrolimus based regimen. Transplant Proc 37 (2005) 867